KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31

KYNTRA BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$5.28+0.43 (+8.87%)

Close on Oct 19, 2026

Market cap: $21.37M
P/E (TTM): 0.1
Dividend yield: –

KYNTRA BIO, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	6.44	30	47	141	235	176	257	213	131	183	181	138	102
Cost of Revenue	0.56	16	3.96	20	13	8.87	1.15	–	–	–	–	–	–
Gross Profit	5.88	14	43	120	222	167	255	–	–	–	–	–	–
Research & Development	24	96	266	297	387	253	209	236	197	187	214	151	86
Selling, General & Admin	28	49	86	125	124	106	135	64	52	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	64	52	46	44	37	24
Operating Expenses	–	–	–	–	–	368	346	300	248	233	258	188	110
Total Costs & Expenses	52	180	370	442	524	368	346	–	–	–	–	–	–
Operating Income	-46	-150	-323	-301	-289	-192	-89	-87	-117	-50	-78	-50	-7.95
Interest Expense	8.76	8.25	8.10	1.44	1.08	2.40	2.88	11	9.71	11	11	11	11
Income from Equity Investments	–	–	2.64	1.57	1.01	-0.20	0	–	–	–	–	–	–
Other Non-Operating Income	2.94	5.30	7.59	7.60	-1.08	5.55	16	–	–	–	–	–	–
Merger & Restructuring Charges	0.55	19	13	0	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	-2.55	0.00	0.00	-0.23	-0.93	0.04	-0.05	0.00	0	-0.10	0.01	0.00
Pretax Income	-58	-153	-323	-295	-291	-189	-77	-86	-121	-58	-86	-60	-15
Income Tax Expense	-0.09	-0.27	-0.25	0.36	0.35	0.36	0.33	0.30	0.32	-0.07	0.24	0	0
Income from Continuing Operations	-58	-153	-323	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	242	106	39	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	183	-48	-284	-294	-290	-189	-77	-86	-121	-58	–	–	–
Net Income	183	-48	-284	-294	-290	-189	-77	-86	-121	-58	-86	-60	-15
EPS (Basic)(per share)	45.37	-11.89	-73.00	-78.50	-78.50	-52.75	-22.25	-25.75	-41.50	-23.25	-35.50	-79.25	-28.25
EPS (Diluted)(per share)	45.37	-11.89	-73.00	-78.50	-78.50	-52.75	-22.25	-25.75	-41.50	-23.25	-35.50	-79.25	-28.25
Shares Outstanding (Basic, Weighted)(shares)	4.04	4.00	3.89	3.74	3.69	3.59	3.47	3.36	2.92	2.51	2.41	0.75	0.53
Shares Outstanding (Diluted, Weighted)(shares)	4.04	4.00	3.89	3.74	3.69	3.59	3.47	3.36	2.92	2.51	2.41	0.75	0.53

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 6.3%
Operating margin: -1089.8%
Net margin: 3967.8%
Return on equity, FY2025: -143.5%

Financial strength

Current ratio: 2.69
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 140.5%

Valuation

P/E ratio: 0.1
Price to sales: 4.63
Price to book: –
Dividend yield: –